Sensyne Health has partnered with Microsoft to launch its SENSE clinical diagnosis algorithm engine in the UK. 

The listed HealthTech has signed its first agreement with Chelsea & Westminster Hospital NHS Foundation Trust for an algorithm produced by the SENSE system.  

The algorithm, called SYNE-COVTM, aims to provide more personalised care for patients with COVID-19, integrating data into an existing real-time dashboard allowing clinicians to augment their clinical decisions with near realtime risk prediction for three outcomes: risk of ICU admission, the need for mechanical ventilation and in-hospital mortality. 

Sensyne CEO Lord Drayson said the algorithm is “designed and built to help the NHS cope with a potential second wave of COVID-19“. 

A real-time decision support service for clinicians across multiple conditions, SENSE has been developed with Microsofts health cloud technology as part of an existing strategic partnership between the two organisations. 

Sensyne says SYNEs enable clinicians and health systems to input up-to-date information on their patients, which is analysed using machine learning against the SENSE database of millions of patients and then provide reasoned advice to take rapid, informed clinical decisions and improve operational efficiency. 

Other SYNE algorithms for different conditions are currently being developed and are expected to be announced in due course. 

Sensyne intends to launch its SENSE system and associated SYNE algorithms in the United States towards the end of the current financial year, with global deployment planned. 

“The SENSE system is a major step forward in unifying different elements of our clinical AI technology together with Microsoft’s health cloud technology to deliver multiple clinical algorithms at scale,” said Drayson.  

We are delighted to announce the first SYNE algorithm from this approach, developed in collaboration with Chelsea & Westminster NHS Foundation Trust, designed and built to help the NHS cope with a potential second wave of COVID-19.” 

Robert Hodgkiss, Deputy Chief Executive Chelsea & Westminster Hospital NHS Foundation Trust, said: “Chelsea and Westminster has a long tradition of innovation. It supports our key purpose to provide high quality care for patients and making the best use of resources.  

We took major steps forward in our agile working during the COVID-19 pandemic and we are committed to supporting our clinicians to make crucial treatment decisions on the front line.  

We are proud of the development of this product and its potential for patient benefit.”